Cipla logged healthy gains in trade after it acquired Hetero Drugs US business for $550 million earlier in the day. In an exclusive chat with ET NOW's Nikunj Dalmia, Subhanu Saxena - MD & Global CEO of Cipla said that the acquisition has potential to add $200 mn to the revenues this year. To know more on the deal, listen in to the man himself.
